10x Genomics Sues Element Biosciences, Alleging Infringement of Spatial RNA Analysis Tech
The lawsuit, filed May 8, is 10x Genomics’ latest patent tilt in the field of spatial transcriptomics.
10x Genomics has sued Element Biosciences, alleging infringement of patents covering spatial transcriptomics
In a complaint filed May 8 in the US District Court for the District of Delaware, 10x Genomics alleged that Element’s Aviti24 multiomics technology infringes four patents licensed from Harvard University.
10x Genomics asked for a judgment that Element infringes its patents, permanent injunctions against Element, a jury trial, and damages.
Element launched Aviti24 in 2024 as an upgrade to its benchtop sequencing instrument that also offers the ability to do analysis of RNA, proteins, and cell structure.
10x Genomics offers single-cell and spatial transcriptomics technologies, including the recently launched Atera platform. It has been involved in multiple lawsuits over spatial RNA analysis, including with Illumina, NanoString Technologies (now part of Bruker), and Vizgen.
Element should have known about 10x’s IP, the company argued, because:
Both the NanoString and Vizgen cases were widely known in spatial biology. See, e.g., Andrew P. Han, 10x Genomics Sues NanoString, Vizgen Over Spatial Gene Expression Analysis Technologies, GenomeWeb, May 10, 2022.
10x also said it subpoenaed Element as part of the NanoString and Vizgen cases.